JDRF expands beta cell research partnership
JDRF has extended a jointly-funded research programme with Johnson & Johnson (which has the diabetes-specific Lifescan and Animas brands in the UK) focused on developing therapies
JDRF has extended a jointly-funded research programme with Johnson & Johnson (which has the diabetes-specific Lifescan and Animas brands in the UK) focused on developing therapies
In an aticle from Diabetes Newshound, “Once Type 1 diabetes begins to develop, there is no stopping it. While the process can take years, the
GlaxoSmithKline says that Otelixizumab, a Type 1 drug currently under development, has failed in a phase III clinical trial. The drug has been in development
Research recently published in the The Lancet has indicated that early studies into a new basal insulin option for people with type 2 diabetes, which
Researchers are saying that ultra-tight blood sugar control in Type 2 diabetics considered to be high-risk patients may not necessarily be a good thing, according
Researchers say they have discovered a new way in which beta cells in the pancreas are destroyed, according to a recent article posted on dLife.
Researchers from the University of New South Wales, Australia, reviewed 26 previous studies examining enterovirus infection and Type 1 diabetes, involving a total of 4,448 people.
A Cavalier King Charles Spaniel named Pascoe sniffs out diabetes among inmates in the Junee Prison in southern New South Wales, Australia. Pascoe is being
To find out why some diabetics develop complications and others don’t, researchers are examining 12,000 people in Sweden. All study participants have had diabetes for
Eli Lilly and Company (NYSE: LLY) and the Juvenile Diabetes Research Foundation (JDRF) announced in early February 2011 that they have signed an agreement to